Cancer treatment-induced mucositis pain: strategies for assessment and management

Debra J Harris, Debra J Harris

Abstract

Mucositis pain is a major clinical problem associated with cancer treatment. Mucosal tissue injury is a dose-limiting side effect and also limits nutritional intake and oral function, resulting in weight loss and nutritional deficits for many patients. The pathophysiology of mucositis is thought to be a complex array of cytokine-mediated events, which begins with mucosal atrophy and eventually leads to the painful ulceration of the mucosa. This article reviews current research related to pain management for mucositis. Effective treatment for mucositis pain must be targeted at the various factors involved in the pain experience. Although a number of interventions aimed to prevent and treat mucositis have been studied, there is little evidence to recommend any one treatment modality. While current strategies for pain management rely on general treatment for acute pain, research developments are aimed at targeting the specific receptors and enzymes involved in mucositis. As these breakthroughs become available clinically, thorough assessment and timely directed interventions must be implemented in order to limit patient distress from mucositis. This article presents an assessment tool specific to mucositis pain, including physical, functional, and pain parameters.

References

    1. Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 1998;74:2879–84.
    1. Avritscher EB, Cooksley CD, Elting LS. Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis. Semin Oncol Nurs. 2004;20:3–10.
    1. Bez C, Demarosi F, Sardella A, et al. GM-CSF mouthrinses in the treatment of severe oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:311–15.
    1. Brown CG, Wingard J. Clinical consequences of oral mucositis. Semin Oncol Nurs. 2004;20:16–21.
    1. Camp-Sorrell D. Chemotherapy: toxicity management. In: Yarbro CH, Frogge MH, Goodman M, et al., editors. Cancer nursing principles and practice. 5th ed. Boston: Jones & Bartlett; 2000. pp. 444–86.
    1. Castagna L, Benhamou E, Pedraza E, et al. Prevention of mucositis in bone marrow transplantation: A double blind randomized controlled trial of sucralfate. Ann Oncol. 2001;12:953–55.
    1. Cengiz M, Ozyar E, Ozturk D, et al. Sucralfate in the prevention of radiation-induced oral mucositis. J Clin Gastroenterol. 1999;28:40–3.
    1. Dibble SL, Shiba G, MacPhail L, et al. MacDibbs mouth assessment: a new tool to evaluate mucositis in the radiation therapy patient. Cancer Pract. 1996;4:135–40.
    1. Dodd MJ, Dibble SL, Miaskowski C, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:39–47.
    1. Epstein JB, Schubert MM. Oral mucositis in myelosuppressive cancer therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:273–6.
    1. Epstein JB, Schubert MM. Managing pain in mucositis. Semin Oncol Nurs. 2004;20:30–7.
    1. Ertiz D, Erkal HS, Serin M, et al. Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncol. 2000;36:116–20.
    1. Foncuberta MC, Cagnoni PJ, Brandts CH, et al. Topical transforming growth factor-beta 3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother. 2001;24:384–8.
    1. Graham K, Pecoraro D, Ventura M. Reducing the incidence of stomatitis using a quality assessment and improvement approach. Cancer Nurs. 1993;16:117–22.
    1. Harris DJ, Knopf MT. Assessing and managing chemotherapy-induced mucositis pain. Clin J Oncol Nurs. 2004;8:622–8.
    1. Karthaus M, Rosenthal C, Huebner G, et al. Effect of topical oral G-CSF on oral mucositis: A randomised placebo-controlled trial. Bone Marrow Transplant. 1998;22:781–5.
    1. Kwong KF. Prevention and treatment of oropharyngeal mucositis following cancer therapy. Cancer Nurs. 2004;27:183–205.
    1. Larson PJ, Miaskowski C, MacPhail L, et al. The PRO-SELF Mouth Aware program: An effective approach for reducing chemotherapy-induced mucositis. Cancer Nurs. 1998;21:263–8.
    1. Malik IA, Moid I, Haq S, et al. A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis. J Pain Symptom Manage. 1997;14:82–7.
    1. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150:971–9.
    1. McGuire D. Mucosal tissue injury in cancer therapy. Cancer Pract. 2002;10:179–90.
    1. McGuire DB, Yeager KA, Dudley WN, et al. Acute oral pain and mucositis in bone marrow transplant and leukemia patients: Data from a pilot study. Cancer Nurs. 1998;21:385–93.
    1. Melichar B, Kohout P, Bratova M, et al. Intestinal permeability in patients with chemotherapy-induced stomatitis. J Cancer Res Clin Oncol. 2001;127:314–18.
    1. Mueller BA, Millheim ET, Farrington EA, et al. Mucositis management practices for hospitalized patients: National survey results. J Pain Symptom Manage. 1995;10:510–20.
    1. Peterson DE, Beck SL, Keefe DM. Novel therapies. Semin Oncol Nurs. 2004;20:53–8.
    1. Raber-Durlacher JE, Weijl NI, Abu Saris M, et al. Oral mucositis in patients treated with chemotherapy for solid tumors: A retrospective analysis of 150 cases. Support Care Cancer. 2000;8:366–71.
    1. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs. 2001;61:955–77.
    1. Rose-Ped AM, Bellm LA, Epstein JB, et al. Complications of radiation therapy for head and neck cancers: The patient's perspective. Cancer Nurs. 2002;25:468–9.
    1. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100:2026–46.
    1. Schulz-Kindermann F, Hennings D, Ramm G, et al. The role of biomedical and psychosocial factors for the prediction of pain and distress in patients undergoing high-dose therapy and BMT/PBSCT. Bone Marrow Transplant. 2002;29:341–51.
    1. Sonis ST. Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39–43.
    1. Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2:21–32.
    1. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Eng J Med. 2004;351:2590–8.
    1. Turhal NS, Erdal S, Karacay S. Efficacy of treatment to relieve mucositis-induced discomfort. Support Care Cancer. 2000;8:55–8.
    1. Wojtaszek C. Management of chemotherapy-induced stomatitis. Clin J Oncol Nurs. 2000;4:263–70.
    1. Wong SF, Wilder-Smith P. Pilot study of laser effects on oral mucositis in patients receiving chemotherapy. Cancer J. 2002;8:247–54.
    1. Yeager KA, McGuire DB, Sheidler YR. Assessment of cancer pain. In: Yarbro CH, Frogge MH, Goodman M, et al., editors. Cancer nursing principles and practice. 5th ed. Boston: Jones & Bartlett; 2000. pp. 633–56.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe